APOE-ε2 allele associated with higher pevalence of sporadic Parkinson disease

Xuemei Huang, Peter C. Chen, Charles Poole

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

Background: The link of the apolipoprotein (APOE) -ε4 allele to Alzheimer disease (AD) has led to studies investigating the role of apoE polymorphisms in Parkinson disease (PD). The authors hypothesized that any association between PD and APOE alleles and genotypes would be too small to be detected or precisely estimated by an individual case-controlled study. Method: The hypothesis was tested by systematic review and meta-analysis of results from case-control studies that provided clear clinical or pathologic criteria for PD and that reported APOE genotype frequencies. Published reports were obtained from MEDLINE, Biosis Previews, and ISI Web of Science searches, supplemented by citation analysis from retrieved articles. The authors estimated and compared prevalence odds ratios (OR) for PD in relation to each allele and genotype. Results: Twenty-two eligible studies were identified. There was no evidence of heterogeneity (p > 0.4) or publication bias (p > 0.2) for any allele or genotype. The estimated summary OR for one or more copies of each APOE allele was 1.20 for APOE-ε2 (95% CI, 1.02 to 1.42), 0.83 for APOE-ε3 (95% CI, 0.63 to 1.09), and 0.99 for APOE-ε4 (95% CI, 0.87 to 1.14). Conclusions: Unlike Alzheimer disease, for which the APOE-ε4 allele increases the prevalence and the APOE-ε2 allele is protective, the authors' analysis shows the APOE-ε2 allele, but not the APOE-ε4 allele, to be positively associated with sporadic Parkinson disease.

Original languageEnglish (US)
Pages (from-to)2198-2202
Number of pages5
JournalNeurology
Volume62
Issue number12
DOIs
StatePublished - Jun 22 2004

Fingerprint

Apolipoproteins
Parkinson Disease
Alleles
Genotype
Alzheimer Disease
Odds Ratio
Publication Bias
Apolipoproteins E
MEDLINE
Meta-Analysis
Case-Control Studies

All Science Journal Classification (ASJC) codes

  • Clinical Neurology

Cite this

Huang, Xuemei ; Chen, Peter C. ; Poole, Charles. / APOE-ε2 allele associated with higher pevalence of sporadic Parkinson disease. In: Neurology. 2004 ; Vol. 62, No. 12. pp. 2198-2202.
@article{3a7fce9873374821adb4712d6bf8c745,
title = "APOE-ε2 allele associated with higher pevalence of sporadic Parkinson disease",
abstract = "Background: The link of the apolipoprotein (APOE) -ε4 allele to Alzheimer disease (AD) has led to studies investigating the role of apoE polymorphisms in Parkinson disease (PD). The authors hypothesized that any association between PD and APOE alleles and genotypes would be too small to be detected or precisely estimated by an individual case-controlled study. Method: The hypothesis was tested by systematic review and meta-analysis of results from case-control studies that provided clear clinical or pathologic criteria for PD and that reported APOE genotype frequencies. Published reports were obtained from MEDLINE, Biosis Previews, and ISI Web of Science searches, supplemented by citation analysis from retrieved articles. The authors estimated and compared prevalence odds ratios (OR) for PD in relation to each allele and genotype. Results: Twenty-two eligible studies were identified. There was no evidence of heterogeneity (p > 0.4) or publication bias (p > 0.2) for any allele or genotype. The estimated summary OR for one or more copies of each APOE allele was 1.20 for APOE-ε2 (95{\%} CI, 1.02 to 1.42), 0.83 for APOE-ε3 (95{\%} CI, 0.63 to 1.09), and 0.99 for APOE-ε4 (95{\%} CI, 0.87 to 1.14). Conclusions: Unlike Alzheimer disease, for which the APOE-ε4 allele increases the prevalence and the APOE-ε2 allele is protective, the authors' analysis shows the APOE-ε2 allele, but not the APOE-ε4 allele, to be positively associated with sporadic Parkinson disease.",
author = "Xuemei Huang and Chen, {Peter C.} and Charles Poole",
year = "2004",
month = "6",
day = "22",
doi = "10.1212/01.WNL.0000130159.28215.6A",
language = "English (US)",
volume = "62",
pages = "2198--2202",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

APOE-ε2 allele associated with higher pevalence of sporadic Parkinson disease. / Huang, Xuemei; Chen, Peter C.; Poole, Charles.

In: Neurology, Vol. 62, No. 12, 22.06.2004, p. 2198-2202.

Research output: Contribution to journalArticle

TY - JOUR

T1 - APOE-ε2 allele associated with higher pevalence of sporadic Parkinson disease

AU - Huang, Xuemei

AU - Chen, Peter C.

AU - Poole, Charles

PY - 2004/6/22

Y1 - 2004/6/22

N2 - Background: The link of the apolipoprotein (APOE) -ε4 allele to Alzheimer disease (AD) has led to studies investigating the role of apoE polymorphisms in Parkinson disease (PD). The authors hypothesized that any association between PD and APOE alleles and genotypes would be too small to be detected or precisely estimated by an individual case-controlled study. Method: The hypothesis was tested by systematic review and meta-analysis of results from case-control studies that provided clear clinical or pathologic criteria for PD and that reported APOE genotype frequencies. Published reports were obtained from MEDLINE, Biosis Previews, and ISI Web of Science searches, supplemented by citation analysis from retrieved articles. The authors estimated and compared prevalence odds ratios (OR) for PD in relation to each allele and genotype. Results: Twenty-two eligible studies were identified. There was no evidence of heterogeneity (p > 0.4) or publication bias (p > 0.2) for any allele or genotype. The estimated summary OR for one or more copies of each APOE allele was 1.20 for APOE-ε2 (95% CI, 1.02 to 1.42), 0.83 for APOE-ε3 (95% CI, 0.63 to 1.09), and 0.99 for APOE-ε4 (95% CI, 0.87 to 1.14). Conclusions: Unlike Alzheimer disease, for which the APOE-ε4 allele increases the prevalence and the APOE-ε2 allele is protective, the authors' analysis shows the APOE-ε2 allele, but not the APOE-ε4 allele, to be positively associated with sporadic Parkinson disease.

AB - Background: The link of the apolipoprotein (APOE) -ε4 allele to Alzheimer disease (AD) has led to studies investigating the role of apoE polymorphisms in Parkinson disease (PD). The authors hypothesized that any association between PD and APOE alleles and genotypes would be too small to be detected or precisely estimated by an individual case-controlled study. Method: The hypothesis was tested by systematic review and meta-analysis of results from case-control studies that provided clear clinical or pathologic criteria for PD and that reported APOE genotype frequencies. Published reports were obtained from MEDLINE, Biosis Previews, and ISI Web of Science searches, supplemented by citation analysis from retrieved articles. The authors estimated and compared prevalence odds ratios (OR) for PD in relation to each allele and genotype. Results: Twenty-two eligible studies were identified. There was no evidence of heterogeneity (p > 0.4) or publication bias (p > 0.2) for any allele or genotype. The estimated summary OR for one or more copies of each APOE allele was 1.20 for APOE-ε2 (95% CI, 1.02 to 1.42), 0.83 for APOE-ε3 (95% CI, 0.63 to 1.09), and 0.99 for APOE-ε4 (95% CI, 0.87 to 1.14). Conclusions: Unlike Alzheimer disease, for which the APOE-ε4 allele increases the prevalence and the APOE-ε2 allele is protective, the authors' analysis shows the APOE-ε2 allele, but not the APOE-ε4 allele, to be positively associated with sporadic Parkinson disease.

UR - http://www.scopus.com/inward/record.url?scp=2942711631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942711631&partnerID=8YFLogxK

U2 - 10.1212/01.WNL.0000130159.28215.6A

DO - 10.1212/01.WNL.0000130159.28215.6A

M3 - Article

C2 - 15210882

AN - SCOPUS:2942711631

VL - 62

SP - 2198

EP - 2202

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12

ER -